Teal Health Raises $22M Series A for At-Home HPV Cervical Cancer Screening

Teal Health announced $22M in Series A financing on September 22, 2026. Teal Health raised a $22 million Series A led by .406 Ventures to expand partnerships and access to its at-home HPV cervical cancer screening.

Round details

The financing includes backing from .406 Ventures, Emerson Collective, Forerunner, Serena Ventures, MPower Partners. The company did not publish a valuation with the announcement.

Round: Series A
Capital announced: $22M
Total funding reported: $45M

How the company plans to use the capital

Teal Health said the new capital will fuel a growing network of payor, health system, employer, provider, and brand partnerships and support continued hiring across clinical, commercial, technology, and operational functions. The company also said it is expanding direct-purchase options for individuals and organizations.

Why this matters for GTM teams

Teal Health said the funding comes ahead of January 2027 federal guidelines that will require most health plans to cover self-collection for cervical cancer screening.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Teal Health Series A announcement.